Diageo plc vs Moderna, Inc. — how do they compare? Diageo plc trades at $93.46 (market cap $53.05B), while Moderna, Inc. trades at $62.23 (market cap $24.18B). The key difference: Diageo plc is far larger — about 2.2× Moderna, Inc.'s market cap, and Diageo plc pays a 3.5% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| DEO | MRNA | |
|---|---|---|
Market Cap | $53.05B | $24.18B |
Sector | Technology | Health |
52-Week High | $115.33 | $81.80 |
52-Week Low | $72.47 | $22.36 |
Enterprise Value | $72.54B | $20.33B |
Dividend Yield | 3.5% | — |
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $93.61, down 3.6% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. A new $1 billion savings plan and focus on spirits and Guinness aim to drive a turnaround, with cash flow from operations strong at $4.4 billion in 2026.
The outlook is cautiously optimistic, with analyst consensus leaning buy (49%) amid execution of the cost-cutting strategy. Risks include North America weakness and competitive pressures, but valuation metrics like P/E of 30.5 reflect growth expectations. The stock offers potential for recovery if management delivers on efficiency gains and market share stabilization.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Latest headlines on both assets
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →